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Gram-negative and gram-positive infections have been considered the most important causes of morbidity
and mortality in patients with leukopenia following chemotherapy. However, discrimination between bacterial
infections and harmless fever episodes is difficult. Because classical inflammatory signs of infection are often
absent and fever is frequently the only sign of infection, the aim of this study was to assess the significance of
serum interleukin-6 (IL-6), IL-10, macrophage inflammatory protein-2 (MIP-2), procalcitonin (PCT), and
C-reactive protein (CRP) patterns in identifying bacterial infections during start of fever in normal and
cyclophosphamide-treated (leukopenic) rats following an injection of lipopolysaccharide (LPS) or muramyl
dipeptide (MDP) as a model for gram-negative and gram-positive bacterial infections. We found that, com-
pared to normal rats, immunosuppressed animals exhibited significantly higher fevers and lesser production
of all mediators, except IL-6, after toxin challenge. Moreover, compared to rats that received MDP, both groups
of animals that received an equivalent dose of LPS showed significantly higher fevers and greater increase in
serum cytokine levels. Furthermore, in contrast to those in immunocompetent rats, serum levels of IL-6 and
MIP-2 were not significantly changed in leukopenic animals after MDP injection. Other serum markers such
as PCT and CRP failed to discriminate between bacterial stimuli in both groups of animals. These results
suggest that the use of the analyzed serum markers at an early stage of fever could give useful information for
the clinician for excluding gram-negative from gram-positive infections.
Bloodstream infection is an important cause of morbidity
and mortality, especially in febrile patients undergoing inten-
sive chemotherapy for the treatment of cancer and other ill-
nesses (10). This susceptibility appears to be directly related to
the severity and length of leukopenia (28). Most infections in
immunosuppressed patients are due to gram-negative and
gram-positive bacteria (21), and fever is frequently the only
sign of infection (7, 34). Thus, because in the majority of these
patients with fever episodes the causative infectious agents
cannot be identified due to the nonspecific nature of signs and
symptoms (16), these patients are treated empirically with
broad-spectrum antibiotics as soon as fever develops (6, 28).
Therefore, because there are increasing numbers of patients
who are immunodeficient following chemotherapy and be-
cause microbes are becoming antibiotic resistant, the use of
inflammatory markers for early detection of bacterial infec-
tions could be essential to reflect the nature of the infection
and distinguish the fever episodes in immunosuppressed pa-
tients in order to guide the choice of specific antibiotic thera-
pies, even before culture results are available (27).
The systemic host responses to gram-negative and gram-
positive bacterial infections involve similar clinical symptoms,
including leukocytosis and fever (19, 44). Leukocytes, mainly
neutrophils, are essential for resistance to bacterial infections,
as they are the main source of proinflammatory mediators (25,
32). These cells express specific receptors for immunogenic
bacterial cell wall constituents released during infection (1,
37).
Lipopolysaccharide (LPS) is believed to be the most impor-
tant marker for gram-negative bacteria, whereas peptidoglycan
by-products such as muramyl dipeptides (MDP) serve as sa-
lient stimuli from gram-positive bacteria (9, 19, 20, 44). Al-
though gram-negative bacterial cell walls also contain pepti-
doglycan, its concentration is far greater in the walls of gram-
positive bacteria (20, 44). Muramyl peptides are key elements
of the immune response to gram-positive bacteria, which lack
LPS. Presently, much work is focused on LPS effects, but many
immunocompromised patients die of gram-positive infections
(10). Immune cells activated by binding of these substances
release many inflammatory mediators, including eicosanoids,
cytokines, and chemokines, that activate other immune cells
and can also serve to signal the brain.
In humans and experimental animals, MDP and LPS cause
an induction of the acute-phase response, which is character-
ized by fever and the production of cytokines in vitro and in
vivo (9, 20, 30), with cells and animals being more sensitive to
LPS than to MDP (42). These studies indicate that the patterns
of production of endogenous mediators involved in the pri-
mary nonspecific acute host response may be dependent upon
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the specificity of the microbial pathogens and the host recog-
nition pathways invoked. Like for LPS, it is assumed that MDP
produces fever via cytokines and prostaglandin E2 induction
(20, 44). The mechanisms underlying the febrile response to
LPS and MDP in leukopenic animals were not elucidated in
this study. This point remains to be resolved, although it is
presently under investigation in our laboratory.
Although there are discrepancies regarding the involvement
of specific receptors in recognition of gram-negative and gram-
positive cell wall components (1, 38, 39, 43), LPS and MDP
elicit similar fevers and apparently similar sickness behaviors.
Much evidence now indicates that LPS and MDP activate
different cell surface receptors and that the stimulation of
these different receptors can lead to different pathways and
profiles of proinflammatory mediators (13, 17, 18, 29). More
recently, evidence has accumulated to indicate that, in contrast
to the case for LPS, the response to MDP is CD14 independent
and is recognized by nucleotide-binding oligomerization do-
main 2 but not by Toll-like receptor 2 (TLR2) or TLR4 MD-2
complex (14, 37).
Circulating proinflammatory mediators such as interleukin-6
(IL-6), IL-8, macrophage inflammatory protein-2 (MIP-2), C-
reactive protein (CRP), and, more recently, procalcitonin
(PCT) have been suggested to be predictive for a systemic
microbial bloodstream infection in neutropenic hosts (4, 8, 11,
12, 24, 35, 36). However, the early cellular response to gram-
negative and gram-positive bacteria is still unclear, and little is
known about how the profile of these mediators during severe
leukopenia might be affected by different microbial stimuli.
The present study was established to compare the induction
of fever and proinflammatory mediators (IL-6, IL-10, MIP-2,
CRP, and PCT) in normal and leukopenic rats following an
injection of LPS or MDP as a model to discriminate between
gram-negative and gram-positive infections. For this purpose,
we used an experimental model that resembles the pathophys-
iologic events that may occur in patients receiving cyclophos-
phamide, an alkylating agent with cytotoxic and immunosup-
pressive activities used in the treatment of malignancies and as
a combatant of transplant rejection.
MATERIALS AND METHODS
Animals. Specific-pathogen-free male Wistar rats (Charles River Breeding
Labs, Barcelona, Spain), weighing between 200 and 250 g, were used for the
experiments. Rats were kept in a specific-pathogen-free facility and housed in
individual plastic cages. All rats were maintained during all experiments in a
temperature-, humidity-, and light-controlled chamber set at 26  1°C with a
12-h, 12-h light-dark cycle, with light on at 0700 h. Rodent laboratory chow and
drinking water were provided ad libitum. One rat was used for one experiment
only and was not used repeatedly. Half of the rats were rendered leukopenic by
intraperitoneal (i.p.) injections of cyclophosphamide before bacterial challenge,
whereas the nonleukopenic group (normal, immunocompetent rats) did not
receive any cyclophosphamide. All rats were acclimated for 1 week before the
study. Experimental interventions were carried out with the rats remaining in
their home cages. Care and use of the animals were in accordance with protocols
approved by the Animal Ethics Committee of the University of Seville and were
conducted according to the European Communities Council Directive (86/609/
EEC).
Drug solutions. Cyclophosphamide, purified lipopolysaccharide from Esche-
richia coli (serotype 0111:B4), and MDP (N-acetyl-muramyl-L-alanyl-D-isoglu-
tamine) were obtained from Sigma Chemical Co. (St. Louis, MO). The vehicle
for all solutions was sterile, pyrogen-free 0.9% saline (PFS) (Fresenius Kabi,
Barcelona, Spain). The same lot and stock solutions were used for all experi-
ments. All drug solutions were prepared in pyrogen-free glassware, passed
through 0.22-m-pore-size Millipore bacterial filters, warmed to 37°C, and
briefly sonicated before i.p. administration. None of the MDP and cyclophos-
phamide solutions used in this study induced gelation in the Limulus amebocyte
lysate assay, so any contamination with endotoxin was below the level of 25
pg/ml.
Body temperature measurement. Changes in core body temperature were
measured every 5 min using remote radiobiotelemetry (Vitalview Series 4000
system; Mini Mitter, Sunriver, OR) with an accuracy of 0.1°C. Briefly, anes-
thetized animals (100 mg/kg ketamine and 5 mg/kg xylazine, both administered
by i.p. injection), were implanted i.p. with precalibrated temperature-sensitive
radio transmitters (model PDT-4000 E-Mitters; Mini Mitter). Each animal was
housed in a separate cage and allowed to recover for 1 week. The regular
day-night body temperature rhythm was monitored for another week before the
experiment. Animals remained in their home cages during the experiment, while
the frequencies emitted by the thermistors were monitored remotely. These
frequencies were then converted to temperature (°C) values based on each
transmitter’s calibration data. For the analysis and graphical documentation,
temperature data from adequate time intervals of 15 min were used.
Induction of leukopenia. Chemotherapy-induced profound leukopenia in rats
was achieved as described previously (24, 26). In brief, rats were rendered
leukopenic by i.p. administration of cyclophosphamide at 150 and 50 mg/kg, 3
days and 1 day, respectively, before injection or any further treatment. This
protocol resulted in leukocyte counts of 0.1  109/liter on the day of drug
injection (day 0), mainly due to a very low number of neutrophils. Also, the
numbers of lymphocytes and monocytes are strongly reduced and contribute to
the profound leukopenia observed in this experimental model (see Table 1).
Animals were monitored for evidence of overt illness, activity, and body tem-
perature after the treatments. No animals died following cyclophosphamide
administration.
Experimental procedures. All experiments were conducted between 0700 and
1900 h. so that the circadian rhythms of the animals were identical across studies.
Before the experiment, rats were weighed and arbitrarily assigned to body
weight-matched experimental groups. Only animals whose body temperatures
were stable and in the range of 36.9 to 37.3°C, which is within the range usually
observed for rats under similar experimental conditions (23, 24), and which were
acclimated to experimental procedures were used to determine the effect of drug
application. All treatments were carried out at the same time of day, with each
rat being used only once for the experiment. On the day of the experiment, the
animals were separated into three treatment groups, namely, LPS, MDP, and
PFS; each rat was handled gently so that the body temperature stabilized for a
period of at least 90 min before any injection. For body temperature and hema-
tological studies as well as the quantitative determination of inflammatory me-
diators, separate groups of normal and leukopenic rats were used in a time
course experiment (n  10 to 12 rats/group/time point).
Fever induction. Fever was induced by i.p. administration of a single dose of
LPS (100 g/kg) or MDP (100 g/kg), as previously described (23, 30, 33, 41).
Control animals received an equivalent volume of PFS as vehicle (1 ml/kg). The
order of PFS and pyrogen injections was randomized. All LPS and MDP treat-
ments were carried out 24 h after the second injection of cyclophosphamide,
when leukocyte counts are very low (see Table 1). To avoid the development of
toxin tolerance, each animal was injected with LPS or MDP only once. All
injections were done at the same time of day (0700 h), so that the circadian
rhythms of the animals were identical across studies. The changes in core body
TABLE 1. Effect of cyclophosphamide on total leukocytes and
differential cell counts in ratsa
Cells
Count (109/liter)b in:
PFS-treated rats Cyclophosphamide-treated rats
Total leukocytes 6.0  0.3 0.1  0.02*
Neutrophils 4.2  0.3 0.06  0.02*
Lymphocytes 1.5  0.2 0.008  0.001*
Monocytes 0.3  0.1 0.01  0.001*
a At 24 h after the second dose of cyclophosphamide or PFS, immediately
before LPS or MDP treatment (day 0), numbers of total leukocytes, neutrophils,
monocytes, and lymphocytes in the peripheral bloodstream were determined.
b Data represent the means ( SEM) for 10 rats in each treatment group. *,
significantly different from the corresponding values in immunocompetent rats
(P  0.05 by ANOVA)
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temperatures were monitored for 12 h posttreatment. For hematological studies
and the quantitative determination of inflammatory mediators, additional groups
of normal and leukopenic rats were used. Blood samples were collected from rats
anesthetized as described above via cardiac puncture (under terminal anesthesia)
at selected times after drug injection for later measurement of cell counts and
serum mediators.
Hematological parameters. For hematological studies, whole blood for cell
counts was collected into sterile tubes containing K3EDTA, and cells were
counted by an automatic hematological analyzer equipped with veterinary soft-
ware (Cell Dyne 3500; Abbot, Allentown, PA), which uses a laser beam and
measures the light scattered by the cells to give the total and differential leuko-
cyte counts. Total peripheral leukocytes, lymphocytes, monocytes, and neutro-
phils counts were determined at 1, 2, 4, 8, and 12 h after LPS, MDP, or PFS
administration for both normal and cyclophosphamide-treated rats.
Inflammatory mediators. For measurement of IL-6, IL-10, MIP-2, CRP, and
PCT production in serum, blood was collected into sterile tubes containing
trisodium citrate and a proteinase inhibitor mixture (125 mmol/ml citrate, 5000
mmol/ml EDTA, 6000 mmol/ml N-ethylmaleimide, and 500 kIU/ml aprotinin).
The blood samples were immediately centrifuged at 2,000  g for 10 min at 4°C
and stored at –80°C until the day of analysis (within 1 month). Quantitative
determination of rat cytokines in serum was done by enzyme-linked immunosor-
bent assays, using specific kits for IL-6 (R&D Systems Europe, Abingdon, United
Kingdom), IL-10 (IBL, Hamburg, Germany), and MIP-2 (BioSource Interna-
tional, Camarillo, CA). The lower detection limits were 10 pg/ml for IL-6, 5
pg/ml for IL-10, and 1 pg/ml for MIP-2. The serum PCT concentrations were
measured using a chemiluminescent immunoassay kit (LUMItest PCT;
B.R.A.H.M.S. Diagnostica GMBH, Berlin, Germany) with a lower detection
limit of 0.1 ng/ml. CRP in serum was measured by a particle-enhanced immu-
noturbidometric method, using a Cobas Integra 700 (Roche Diagnostic System,
Basel, Switzerland). All samples were analyzed in duplicate and were assayed at
optimal concentrations, according to the manufacturer’s instructions.
Data analysis. Data are presented as means  standard errors of the means
(SEM) and were analyzed using SigmaStat software (SPSS Inc., Chicago, IL). In
graphs of the thermal and cytokine responses, the mean changes were plotted
over time. Integrated areas under the curve (AUC), from 0 to 12 h posttreat-
ment, were calculated by trapezoid analysis and were used to compare the
differences in the responses of each rat to pyrogen and PFS injections. Data were
analyzed by one-way analysis of variance (ANOVA). In cases where the com-
parisons using ANOVA were shown to be significant, a further test using Stu-
dent-Newman-Keuls post hoc analyses was performed to compare the effect of
each treatment. A P value of 0.05 was considered significant.
RESULTS
Induction of peripheral blood leukopenia by cyclophospha-
mide. As described before, i.p. administration of cyclophos-
phamide induced a severe leukopenia in rats. As shown in
Table 1, the absolute leukocyte count (immunocompetent rats,
5,890  350 cells/ml) was significantly reduced by cyclophos-
phamide (to 100 20 cells/ml) during all experimental periods
(P  0.05), indicating a successful leukopenic model. This
effect remains for 5 to 7 days (28, 32). Although the reduced
number of blood neutrophils characterizes the present leuko-
penia (absolute neutrophil count, 60 cells/ml; P  0.05),
reduced numbers of lymphocytes (8  1 cells/ml) and mono-
cytes (10  1 cells/ml) also contributed to the decreased total
cell count (P  0.05). Some characteristic toxic effects of im-
munosuppressive chemotherapy were noted; e.g., the leukope-
nic rats appeared more inactive and may have lost some
weight. Figure 1 shows the effects of i.p. administration of 100
g/kg LPS or 100 g/kg MDP on the total count of white blood
cells for immunocompetent and leukopenic rats. All immuno-
competent rats had a transient leukopenia at 1 h after MDP or
LPS administration (P  0.05). This leukopenia was followed
by leukocytosis due to a marked recovery in neutrophils to a
level that exceeded the normal level at 4 or 8 h after MDP or
LPS administration, respectively (data not shown). At 12 h,
total peripheral leukocyte counts were similar to preinjection
values (time zero) (P  0.05). However, in contrast to the case
for immunocompetent rats, the same doses of either LPS or
MDP did not modify the leukocyte populations deteriorated
from a normal range due to cyclophosphamide during all ex-
perimental periods (P  0.05).
To determine the influence of peripheral leukocytes on body
temperature and serum IL-6, IL-10, MIP-2, CRP, and PCT
levels for distinguishing gram-negative from gram-positive bac-
terial infections, we serially measured the body temperature
and the serum levels of these mediators in this model of leu-
kopenic rats following i.p. administration of the gram-negative
pyrogen LPS or the gram-positive pyrogen MDP.
Effects of LPS and MDP on body temperature. To test for
the development of a pyrogenic response to LPS or MDP,
normal rats and rats rendered leukopenic with cyclophospha-
mide were injected i.p. with 100 g of either LPS or MDP per
kg (Fig. 2). Importantly, the mean body temperature did not
differ among the experimental groups, and all animals exhib-
ited a similar basal body temperature that ranged between 36.9
and 37.3°C at the time of injection. The body temperature in
the PFS-treated control groups remained stable throughout
the study and was not different among groups (P  0.05).
Intraperitoneal injection of either LPS or MDP caused fever in
both normal and leukopenic rats (Fig. 2A and B). Fifteen
minutes after challenge with 100 g LPS or 100 g MDP, body
temperatures in immunocompetent rats started to rise, and
they reached the peak level at 6 to 8 h in normal rats (Fig. 2A).
The return to the preinjection level was gradual but was es-
FIG. 1. Leukocyte (WBC) counts in peripheral bloodstreams of
immunocompetent and leukopenic rats injected i.p. with 1 ml/kg PFS,
100 g/kg LPS, or 100 g/kg MDP. Leukopenia was induced by ad-
ministration of cyclophosphamide 3 days (150 mg/kg) and 24 h (50
mg/kg) before PFS or pyrogen injection. The values presented are the
means  SEM for 10 to 12 rats per group. , P  0.05 (significantly
different from the control values by one-way analysis of variance).
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sentially completed by 12 h after challenge (Fig. 2A). In con-
trast, the fevers induced by LPS or MDP in leukopenic rats
remained elevated up to 12 h following the injection and were
significantly higher than those of the immunocompetent ani-
mals throughout (P 0.05) (Fig. 2B). Thus, although the onset
latencies of both groups of rats were not significantly different,
the postfebrile recovery after LPS and MDP administration in
leukopenic animals was not completed after 12 h after pyro-
genic stimuli, and there was a significant enhancement in the
fever (Fig. 2C). By 96 h postinjection, body temperature de-
clined to or near to preinjection values (data not shown). As
shown in Fig. 2C, injection of LPS or MDP in leukopenic rats
resulted in a significant increase in core body temperature,
which was significantly higher than that of the immunocompe-
tent group (Fig. 2C). Furthermore, the febrile response evoked
by LPS was significantly higher than that evoked by an equiv-
alent dose of MDP in both groups of rats (Fig. 2C) (P  0.05).
Effects of LPS and MDP on serum inflammatory mediators.
In addition to measurement of core body temperatures, the
kinetics of IL-6, IL-10, MIP-2, CRP, and PCT in response to
LPS or MDP challenge were also studied. Significant differ-
ences were found between the kinetics of production of these
mediators in normal and leukopenic rats, as well as in LPS- and
MDP-treated rats. High secretion of IL-6, IL-10, MIP-2, PCT,
and CRP was noted in sera of both immunocompetent and
leukopenic rats after injection of a pyrogenic dose of either
LPS or MDP (Fig. 3 and 4). We found for normal (nonleuko-
penic) rats that, in parallel with the body temperature change,
the concentrations of IL-6 (Fig. 3A), IL-10 (Fig. 3C), MIP-2
(Fig. 3E), and CRP (Fig. 4C) in serum also started to rise at
1 h, reached the peak level at 2 to 4 h after LPS or MDP
injection, and returned to the preinjection values at 12 h after
challenge. However, unlike the case for these mediators, PCT
started to rise at 2 h and reached its peak at 8 h after LPS or
MDP administration (Fig. 4A), compared to the respective
PFS controls. Furthermore, as shown in Fig. 5, LPS evoked a
significantly higher production of serum mediators in both
immunocompetent and leukopenic rats compared with the re-
sponses evoked by an equivalent dose of MDP (P  0.05).
In leukopenic rats, the concentrations of IL-6 (Fig. 3B),
IL-10 (Fig. 3D), and MIP-2 (Fig. 3F) in serum also started to
rise at 1 h after LPS challenge. However, in contrast to those
in immunocompetent rats, serum IL-6 and MIP-2 levels in rats
treated with MDP did not differ from those in leukopenic rats
treated with their respective PFS controls at any time point.
Compared to leukopenic animals, the peak levels of all medi-
ators, except for IL-6, were significantly higher in immunocom-
petent rats (Fig. 5) (P  0.05). Similar to the case for immu-
nocompetent rats, PCT and CRP failed to discriminate
between bacterial stimuli in leukopenic rats (Fig. 4B and D).
The comparative study using analysis of integrated areas
under the curve during the early phase of LPS- or MDP-
induced fever showed significant differences between immuno-
competent and leukopenic rats (Fig. 5). Baseline levels of IL-6,
CRP, and PCT in serum were significantly higher in leukopenic
rats. In contrast, baseline levels of MIP-2 were significantly
higher in immunocompetent animals, and those of IL-10 were
not detectable in either group of rats. Injection of LPS or MDP
evoked a significant decrease in IL-10, MIP-2, and PCT levels
in leukopenic rats compared to immunocompetent rats (P 
FIG. 2. Effect of LPS and MDP on body temperature in immuno-
competent and leukopenic rats. Mean changes of core body tempera-
ture (Tc) were determined in separate groups of immunocompetent
(A) and leukopenic (B) rats during 12 h after i.p. injection of either
PFS (), 100 g/kg LPS (F), or 100 g/kg MDP (E). The mean
baselines of absolute body temperatures at time zero for the groups
were not significantly different (36.9 to 37.3°C). Integrated thermal
responses (C) (AUC) of immunocompetent and leukopenic rats after
administration of LPS (black bars), MDP (hatched bars), or PFS
(white bars) were calculated for the whole 12-h recording period from
the data shown in panels A and B (10 to 12 rats under each condition).
Data are expressed as means  SEM. § and , statistically significant
differences (P  0.05) between LPS- and MDP-treated rats and nor-
mal rats, respectively. ‡, significantly different (P  0.05) from corre-
sponding values between immunocompetent and leukopenic rats
(ANOVA, Student-Newman-Keuls post hoc test).
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0.05) (Fig. 5). By contrast, IL-6 production was significantly
higher in leukopenic rats than in immunocompetent rats after
LPS administration (P  0.05) but not after MDP administra-
tion (P 0.05). Both groups of rats that received MDP showed
lesser increases in serum IL-6 (Fig. 5A), IL-10 (Fig. 5B), and
MIP-2 (Fig. 5C) production than were observed in rats that
received a similar dose of LPS. Finally, PCT and CRP failed to
discriminate between bacterial stimuli in both groups of ani-
mals (Fig. 5D and E).
DISCUSSION
The present findings indicate that cytokines such as IL-6,
IL-10, and MIP-2 are rapid and sensitive markers to differen-
FIG. 3. Effects of LPS and MDP on serum IL-6, IL-10, and MIP-2 levels in immunocompetent and leukopenic rats. Serum levels of IL-6 (A and
B), IL-10 (C and D), and MIP-2 (E and F) in separate groups of immunocompetent and leukopenic rats were determined at 1, 2, 4, 8, and 12 h
after i.p. injection of either PFS (), 100 g/kg LPS (F), or 100 g/kg MDP (E). Each experiment involved 10 to 12 rats per time point. At all
time points tested after injection of PFS (control), immunocompetent and leukopenic rats showed no significant elevation in serum levels of these
cytokines (P 0.05). Symbols represent means; bars indicate SEM. , P 0.05 between LPS- and MDP-injected rats (ANOVA, Student-Newman-
Keuls post hoc test) for the same time point.
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tiate gram-negative from gram-positive stimuli in immunocom-
petent and, especially, in leukopenic rats when measured at an
early stage of fever induced by specific pyrogens, such as LPS
and MDP. Our results further suggest that CRP and PCT are
not specific markers to discriminate between these bacterial
infections. We have chosen these inflammatory markers be-
cause of interrelationships in the primary nonspecific host re-
sponse to microbial infection (11, 12, 17, 18). The levels of
other cytokines, such as IL-1 or tumor necrosis factor, were not
determined in the present study because of poorer predictive
value for the presence of bloodstream infection in patients with
fever (15).
Gram-negative and gram-positive organisms have been con-
sidered the most important causes of infection in leukopenic
patients who undergo chemotherapy. It is therefore not sur-
prising that bacterial constituents that are present on the out-
side of the cell and therefore readily accessible to detection
have been selected by the immune system as indicators of
bacterial presence and potent inducers of a host response.
During a bacterial infection in neutropenic patients, it is of
vital importance to the infected host that the presence of
pathogenic bacteria is detected as soon as possible, since these
patients present a high morbidity and this may lead to mortal-
ity if the infection is treated inappropriately or too late. The
present knowledge regarding endogenous inflammatory medi-
ators in leukopenic patients is limited but indicates that the
host response to microbial infection is mediated by the release
of some pyrogenic mediators into the bloodstream (see the
introduction).
Studies with immunocompromised patients have shown that
these patients are capable of producing high serum concentra-
tions of several mediators during severe systemic bacterial in-
fection (4, 11, 21). In febrile neutropenic patients, elevated
circulating IL-6 and IL-8 also predicted microbial infection (8,
12). In some reports, significant differences in the serum levels
of different inflammatory mediators between gram-negative
and gram-positive infections were described. Several investiga-
tors found differences between neutropenic patients with and
without bacteremia and/or differences between gram-negative
and gram-positive bacteremia. The latter observations, how-
FIG. 4. Effects of LPS and MDP on serum CRP and PCT levels in immunocompetent and leukopenic rats. Serum levels of CRP (A and B)
and PCT (C and D) in separate groups of immunocompetent and leukopenic rats were determined at 1, 2, 4, 8, and 12 h after i.p. injection of either
PFS (), 100 g/kg LPS (F), or 100 g/kg MDP (E). Each experiment involved 10 to 12 rats per time point. At all time points tested after injection
of PFS, both immunocompetent and leukopenic rats showed no significant elevation in serum levels of these mediators (P  0.05). Symbols
represent means; bars indicate SEM. , P  0.05 between LPS- and MDP-injected rats (ANOVA, Student-Newman-Keuls post hoc test) for the
same time point.
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ever, are difficult to interpret. Many patients with other causes
of fever are omitted from such an analysis, but they need to be
considered in order to calculate true sensitivities and specific-
ities.
A key event in the initiation of fever in response to acute
bacterial infection is the induction and release of endogenous
pyrogens (i.e., IL-1, IL-6, IL-8, RANTES, and MIPs) by poly-
morphonuclear and mononuclear leukocytes into the blood-
stream (19, 23, 32, 40, 41, 44). Normal leukocytes contain no
detectable pyrogen and do not produce any during in vitro
incubation. After stimulation, however, pyrogen production
begins within a few hours and continues at a steady rate for
12 h or more (5). The key event is a rapid activation of humoral
cascade systems and of leukocytes that support the inflamma-
tory reaction. These cells are thought to be an essential target
for gram-positive and gram-negative bacteria, as they are the
main source of inflammatory mediators involved in the host
acute response to these organisms (32). We found that leuko-
penic rats exhibit higher fevers after systemic injection of LPS
and MDP than immunocompetent rats, despite lower increase
in circulating mediators. Moreover, we found that, indepen-
dently of the immune status, rats that received similar doses of
LPS showed higher fevers and greater increases in serum cy-
tokine levels than those observed after MDP challenge. Inter-
FIG. 5. Mean integrated IL-6 (A), IL-10 (B), MIP-2 (C), CRP (D), and PCT (E) responses of immunocompetent and leukopenic rats after PFS
(white bars), LPS (black bars), or MDP (hatched bars) challenge. Statistical analysis was performed on AUC data from 0 to 12 h after the time
of injection and was calculated from the data shown in Fig. 3 and 4. Bars represent means  SEM for each group of rats (nd, not detected). § and
, statistically significant differences (P  0.05) between LPS-and MDP-treated rats and their respective PFS-treated groups, respectively. ‡,
significantly different (P  0.05) from corresponding values between immunocompetent and leukopenic rats (ANOVA, Student-Newman-Keuls
post hoc test).
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estingly, febrile responses actually subsided before the disap-
pearance of elevated levels of serum cytokines after injection
of LPS and MDP in leukopenic rats. These results are consis-
tent with the idea that even when cytokines are detected in the
blood, their timing does not always correlate with acute-phase
activation after administration of immune stimuli (19).
Concerning the role of administration of cyclophosphamide,
it has previously been shown that this immunosuppressive drug
induces a nonspecific leukopenia (fewer than 100 cells/ml for 6
to 7 days) (24, 26) and a selective depletion of the lymphoid
tissue (2, 42). When such treated patients become afflicted with
a bacterial infection, they develop high fevers. These results
suggest that a lesser contribution of leukocytes may be impor-
tant to the exaggerated fever that occurs in leukopenic pa-
tients. However, in addition to peripheral blood leukocytes, the
tissue resident macrophages are required for host defense
against acute bacterial infection. In this context, production of
cytokines at the tissue level, rather than in circulation, could be
an alternative pathway for the induction of the signal leading
to fever in leukopenic animals.
Because the liver is the principal organ for LPS clearance
and its resident macrophages, the Kupffer cells, are a major
source of pro- and anti-inflammatory cytokines, it has been
suggested that these cells could be central to production of
fever by LPS (44). However, the activity of Kupffer cells is also
depressed by cyclophosphamide in mice and rats (2, 22), and
temporary blockade of these cells with gadolinium chloride, a
substance known to eliminate Kupffer cells (31), did not pre-
vent the febrile response to i.p. LPS in leukopenic rats (E.
Tavares, unpublished data). These results indicated that other
cells types (fibroblasts, endothelial cells, glial cells, etc) in-
volved in the acute inflammatory response are major sites of
the action of bacterial toxins in immunosuppressed rats.
The present results indicate that cytokines such as IL-6,
IL-10, and MIP-2 are regulated or released independently of
the leukocyte count. How the absence of leukocytes leads to an
intensified rather than a reduced febrile response to LPS and
MDP and an associated decreased production of circulating
inflammatory mediators is still unknowable. That is, the reduc-
tion of circulating leukocytes by cyclophosphamide caused sig-
nificantly enhanced fevers (in both magnitude and duration),
and this effect was associated with a significant reduction of
circulating inflammatory cytokines compared to those in im-
munocompetent animals. The present findings confirm previ-
ous experimental and clinical studies that show that the pro-
duction of fever was not dependent on the presence of
leukocytes in the peripheral circulation (3, 24, 28). Further-
more, they suggest that other, yet-to-be identified mediators as
possible mechanisms of immune signaling are involved in the
development of the acute-phase response to gram-negative
and gram-positive infections. Together, these findings suggest
that in immunosuppressed animals leukocytes may play a “neg-
ative” role in the development of a fever induced by exogenous
pyrogens. However, further studies on the pathophysiology of
fever and the contribution of early markers regulated or re-
leased independently of the leukocyte count are necessary to
verify this hypothesis.
Our findings suggesting that the patterns of early production
of proinflammatory mediators may be dependent upon the
specificity of the microbial pathogens are in agreement with
recent studies (13). The differences in the cytokine pattern and
the febrile responses to LPS and MDP may correspond to the
different cell surface receptors stimulated by these bacterial
pyrogens, with leukopenic animals being more sensitive to LPS
than to MDP, which is in agreement with previous in vitro and
in vivo studies (43). Functional characterization of TLRs has
established that innate immunity is a skillful system that de-
tects invasion of microbial pathogens. Recognition of micro-
bial components by TLRs initiates signal transduction path-
ways, which triggers expression of genes. These gene products
control innate immune responses and further instruct devel-
opment of antigen-specific acquired immunity (37). In agree-
ment with these findings, the present results indicate that the
patterns of production of endogenous mediators involved in
the primary nonspecific acute host response may be dependent
upon the specificity of the microbial pathogens and the host
recognition pathways invoked.
The present findings also illustrate the potential differences
in the patterns of whole-blood leukocytes in response to two
disparate, but common, bacterial stimulants. Taking all these
data together, it is improbable that the pyrogenic effects of LPS
and MDP seen clinically in leukopenic patients are directly and
exclusively due to stimulation of pyrogen production by leuko-
cytes. Overall, serum IL-6, IL-10, and MIP-2 levels are able to
discriminate between gram-negative and gram-positive infec-
tion at start of fever in both immunocompetent and leukopenic
rats with acceptable specificity. Furthermore, they suggest that
the exaggerated fever response occurring after LPS injection in
leukopenic animals is partially mediated via IL-6. On the other
hand, CRP and PCT are not sensitive markers in distinguishing
these types of infections. However, although we used an ex-
perimental rat model that resembles the pathophysiologic
events that may occur in leukopenic patients, the findings re-
ported here cannot necessarily be extrapolated to the response
to different gram-negative or gram-positive pathogens or their
constituents in immunosuppressed patients. The mechanisms
underlying the febrile response to LPS and MDP in leukopenic
animals were not elucidated in this study. This point remains to
be resolved, although it is presently under investigation in our
laboratory.
The data presented here extend the argument that LPS and
MDP induce differential fever responses and cytokine profiles
in normal and immunodeficient animals. Finally, these results
indicate that the determination of the serum pattern of specific
inflammatory markers at the onset of fever may be used as an
early diagnostic tool to differentiate gram-negative from gram-
positive infections in both immunocompetent and leukopenic
hosts. A rapid bedside test may thus help guide the choice of
specific antibiotic therapies, especially for neutropenic pa-
tients, even before culture results are available.
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